PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1424970
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1424970
Disposable IV Therapy Products Market size was valued at USD 2,837.22 Million in 2023, expanding at a CAGR of 6.1% from 2024 to 2032.
Disposable IV therapy products are medical devices specifically designed for intravenous (IV) therapy. This essential medical procedure involves the direct delivery of fluids, medications, and other treatments into a patient's bloodstream through a vein. These disposable products are created for single-use purposes, serving to prevent the risk of infection and guarantee patient safety. For example, a sterile disposable IV infusion set is utilized to safely administer fluids and medication to the patient, while also providing ongoing venipuncture access for blood sampling. Additionally, the ADVIN infusion set is specifically designed for delivering insulin under the skin. It comprises a comprehensive tubing system that connects an insulin pump to the user, including a subcutaneous cannula, adhesive mount, quick disconnect, and a pump cartridge connector. The specific disposable IV therapy products employed may vary depending on the healthcare setting, patient requirements, and the type of treatment being administered. Healthcare professionals strictly adhere to rigorous protocols to ensure the utmost safety and effectiveness of IV therapy.
Disposable IV Therapy Products Market- Market Dynamics
An increasing number of patients suffering from chronic diseases are expected to augment market growth
Chronic illnesses such as cancer, diabetes, cardiovascular diseases, and autoimmune disorders often necessitate regular administration of medications, fluids, or other therapeutic agents through intravenous routes. This ongoing need for IV therapies contributes to the demand for disposable IV therapy products. A significant portion of the American population, six out of ten individuals, live with at least one chronic disease, including heart disease, stroke, cancer, or diabetes. These chronic diseases are the primary causes of death and disability in the United States, and they also contribute significantly to healthcare expenses. The World Health Organization reports that cardiovascular diseases account for the highest number of deaths due to non-communicable diseases, with 17.9 million people succumbing to them annually. Cancers follow closely with 9.3 million deaths, chronic respiratory diseases with 4.1 million deaths, and diabetes with 2.0 million deaths, including those caused by kidney disease related to diabetes.
Disposable IV Therapy Products Market- Key Insights
As per the analysis shared by our research analyst, the global Disposable IV Therapy Products market is estimated to grow annually at a CAGR of around 6.1% over the forecast period (2024-2032)
Based on product type segmentation, IV Catheters was predicted to show maximum market share in the year 2023
Based on End-User segmentation, hospitals were the leading type in 2023
Based on region, North America was the leading revenue generator in 2023
The Global Disposable IV Therapy Products Market is segmented based on Product Type, End-User, and Region.
The market is divided into five categories based on product type: IV Catheters, Infusion Sets, IV Cannulas, Stopcocks & Check Valves, Needleless Connectors and Others. The market is primarily dominated by the IV Catheters segment. These catheters have been specifically designed with safety features to minimize the occurrence of needle stick injuries for healthcare providers. Additionally, they frequently incorporate mechanisms that allow for the retraction or covering of the needle post-use.
The market is divided into three categories based on End-User: Hospitals, Clinics and Home Care Settings. The market is largely dominated by the hospital segment. Patient safety is of utmost importance to hospitals, and they adhere to infection control measures by utilizing disposable IV therapy products. By using single-use items, the risk of cross-contamination is minimized, thereby reducing the occurrence of healthcare-associated infections.